en · de · es · fr · pt
cjc-1295-notes.peptides4962.com › Guide › Background And Naming Conventions — Worked Examples

Background And Naming Conventions — Worked Examples

By Editorial Desk · published 2025-07-22 · last reviewed 2025-09-08 · Guide

somatotroph raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-08. Anything still debated is marked as such rather than presented as settled.

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Cjc-1295 at a glance

PropertyValueNotes
Molecular classSynthetic peptideAnalog of growth hormone-releasing hormone
Chain length29 amino acidsBased on the GRF(1-29) fragment
AppearanceWhite to off-white lyophilized powderCommon research supply form
SolubilitySoluble in water and aqueous buffersPowder requires reconstitution before use
Typical storage−20 °C or belowKept away from light and moisture

CJC-1295 Background and Mechanism

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

Related pages on this site

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

Reference notes

Investigational ASO approaches have also been reported for rare genetic epilepsies, including KCNT1-associated developmental and epileptic encephalopathy, where knockdown of KCNT1 has been studied in preclinical human neuronal models and in two treated children, and prenatal targeting

=== Mechanism === Legumain is a cysteine protease from the C13 family of the CD clan of proteases (MEROPS). It uses a catalytic triad of Cysteine-Histidine-Asparagine in its active site to perform covalent proteolysis of its substrate.

=== Bipolar disorder === Endoxifen is used to treat manic or mixed episodes associated with bipolar I disorder in India. It has been found that the endoxifen improves manic symptoms as well as mixed episode symptoms of patients with bipolar I disorder and has been considered an effective and well-tolerated treatment for this condition. Bipolar disorder is associated with overactive protein kinase C (PKC) intracellular signaling. To date, there have been three phases of clinical trials. And, in the phase III trials, endoxifen reduced the total Young Mania Rating Scale (YMRS) score from 33.1 to 17.8. A significant (p < 0.001) improvement in Montgomery–Åsberg Depression Rating Scale (MADRS) score was observed for endoxifen (4.8 to 2.5). The endoxifen is well-tolerated by the subjects as depicted in the changes in Clinical Global Impression-Severity of Illness scores.

The drugs are administered sequentially rather than together for practical and ethical reasons. A mixture could cause the drugs to precipitate from solution, thereby reducing drug delivery and risking pain due to vascular blockage. The potassium chloride, in particular, would cause severe pain as it travels through the bloodstream and distress as it acts upon the heart, were the person not first rendered fully unconscious. The intravenous tubing leads to a room next to the execution chamber, usually separated from the condemned by a curtain or wall. Typically, a prison employee trained in venipuncture inserts the needle, while a second prison employee orders, prepares, and loads the drugs into the lethal injection syringes. Two other staff members take each of the three syringes and secure them into the IVs. After the curtain is opened to allow the witnesses to see inside the chamber, the condemned person is then permitted to make a final statement. Following this, the warden signals that the execution may commence, and the executioner(s) (either prison staff or private citizens depending on the jurisdiction) then manually inject the three drugs in sequence. During the execution, the condemned's cardiac rhythm is monitored. Death is pronounced after cardiac activity stops. Death usually occurs within seven minutes; however, due to complications in finding a suitable vein, the entire procedure can take up to two hours, as was the case with the execution of Christopher Newton on May 24, 2007.

==== Comeback attempt and retirement (2006) ==== On January 23, 2006, the Astros indicated that they would file a claim on an insurance policy on Bagwell's health to collect approximately $15.6 million of the $17 million in salary owed to him for the 2006 season. Days earlier, orthopedic surgeon Dr. James Andrews had performed a physical examination on Bagwell and determined that he had become "completely disabled" and was unable to play baseball again. Because of the language of the policy, the Astros could not release him without losing their settlement, nor could he take the field. The decision effectively eliminated his chances of playing again in the Major Leagues. On March 28, Cigna rejected the claim, contending that because Bagwell had played during 2005 World Series he could not have become more disabled during the period of baseball inactivity characteristic of the offseason. Nonetheless, Bagwell still reported to spring training hoping he could contribute in some way during the upcoming 2006 campaign, and to test the injured shoulder. His mere presence in camp put the Astros' insurance claim into further question, creating an awkward situation between the player and the team. He appeared in 14 spring training games, batting .219 with one double. He never had to make any difficult throws that would place notable stress on his shoulder, as the other infielders shifted toward him. As expected, the Astros put him on the 15-day disabled list in late March with bone spurs in the shoulder.

Sources: en.wikipedia.org

Reference notes

== Contraindications == Plecanatide has not been shown to be safe or effective in persons 6 years to 18 years of age. Use of plecanatide by persons under the age of 6 poses a serious dehydration risk and studies have demonstrated plecanatide can cause death in juvenile mice due to this dehydrating effect. Use of plecanatide is also contraindicated in persons who are suspected of having a mechanical gastrointestinal obstruction.

A gonadotropin-releasing hormone agonist (GnRH agonist) is a GnRH modulator that activates the GnRH receptor resulting in increased secretion of FSH and LH. Initially it was thought that GnRH agonists could be used as potent and prolonged stimulators of pituitary gonadotropin release, but it was soon recognized that GnRH agonists, after their initial stimulating action – termed a "flare" effect – eventually caused a paradoxical and sustained drop in gonadotropin secretion. This second effect was termed "downregulation" and can be observed after about 10 days. While this phase is reversible upon stopping the medication, it can be maintained when GnRH agonists use is continued for a long time. GnRH agonists can also be administered in a pulsatile manner through the use of a pump to produce a long-term stimulation of gonadotropin secretion, for instance to induce puberty.

V.S.O.P. is a 1977 double live album by keyboardist Herbie Hancock, featuring acoustic jazz performances by the V.S.O.P. Quintet (Hancock, trumpeter Freddie Hubbard, saxophonist Wayne Shorter, bassist Ron Carter and drummer Tony Williams), along with jazz fusion/jazz-funk performances by the ‘Mwandishi’ band (trumpeter Eddie Henderson, trombonist Julian Priester, flautist Bennie Maupin, bassist Buster Williams and drummer Billy Hart) and The Headhunters (saxophonist Maupin, guitarists Ray Parker Jr. and Wah Wah Watson, bass guitarist Paul Jackson, percussionist Kenneth Nash and drummer James Levi). The concert was advertised as a "Herbie Hancock Retrospective," and Miles Davis, who was several months into his temporary retirement, was advertised as playing with the V.S.O.P. group (thereby reconstituting Davis’ "Second Great Quintet" for the first time since 1968). According to concert attendees, on the night of the show a handwritten sign was posted on the lobby door announcing that Davis would not be playing, but that Hubbard would be appearing instead.

Global fish production peaked at about 171 million tonnes in 2016, with aquaculture representing 47 percent of the total and 53 percent if non-food uses (including reduction to fishmeal and fish oil) are excluded. With capture fishery production relatively static since the late 1980s, aquaculture has been responsible for the continuing growth in the supply of fish for human consumption. Global aquaculture production (including aquatic plants) in 2016 was 110.2 million tonnes, with the first-sale value estimated at US$244 billion. Three years later, in 2019 the reported output from global aquaculture operations was over 120 million tonnes valued at US$274 billion and by 2022 it had reached 130.9 million tonnes, valued at USD 312.8 billion. For the first time, aquaculture surpassed capture fisheries in aquatic animal production with 94.4 million tonnes, representing 51 percent of the world total and a record 57 percent of the production destined for human consumption. In 2024 aquaculture produced 103 million tonnes of aquatic animals, an all-time record, equivalent to 53% ofglobal aquatic animal output, and over 59% of aquatic animal foods for human consumption. In 2022 most aquaculture workers were in Asia (95%), followed by Africa (3%) and Latin America and the Caribbean (2%). The contribution of aquaculture to the global production of capture fisheries and aquaculture combined has risen continuously, reaching 46.8 percent in 2016, up from 25.7 percent in 2000.

Although looksmaxxers use scientific and medical terminology, the practice is based heavily on anecdotal evidence unsupported by mainstream medicine, and certain aspects—particularly the PSL scale used by practitioners to rate their appearance—are considered pseudoscientific.

Sources: en.wikipedia.org

Frequently asked questions

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

What does the abbreviation DAC refer to?

DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.

Why do different sources report different half-lives for the same name?

Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

Network